Zeralgo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zeralgo

What is Zeralgo?

Zeralgo is a pharmaceutical medication developed for the management of specific pain conditions. It belongs to a class of drugs designed to modulate the body's response to pain signals by interacting with the central nervous system.

Mechanism of Action

The active components in Zeralgo work by influencing the neurotransmitters responsible for transmitting pain messages between nerve cells. By stabilizing electrical activity in the nervous system, the medication helps to reduce the intensity of pain sensations perceived by the patient.

Clinical Applications

Zeralgo is primarily used in the treatment of chronic pain syndromes, particularly those involving nerve-related discomfort. Common applications include:

  • Neuropathic Pain: Managing pain caused by nerve damage or a malfunctioning nervous system.
  • Specific Chronic Conditions: Addressing persistent pain that has not responded sufficiently to first-line analgesic treatments.

Therapeutic Goals

The objective of treatment with Zeralgo is to improve a patient's functional capacity and overall quality of life. Rather than providing an immediate cure, the medication is intended to facilitate long-term symptom management as part of a comprehensive pain care strategy.

Regulatory References

  1. Flurbiprofen on NIH LiverTox

What side effects are possible with Zeralgo?

Possible Side Effects and Safety Information

Zeralgo is associated with a defined risk profile, necessitating careful consideration of its use, as documented in governmental regulatory sources.

Serious and Clinically Significant Adverse Reactions

The drug carries mandated Black Box Warnings from the U.S. Food and Drug Administration (FDA) highlighting two main severe risks:

  • Cardiovascular Thrombotic Events: Increased risk of serious, potentially fatal, cardiovascular events including myocardial infarction (heart attack) and stroke. This risk can occur early in treatment and may increase with duration of use or high doses.
  • Gastrointestinal (GI) Adverse Events: Increased risk of serious GI inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. This can occur without warning symptoms.

Other serious adverse events documented include life-threatening Respiratory Depression, severe Allergic Reactions (including anaphylaxis, especially in aspirin-sensitive patients), and potential long-term Kidney and Liver Damage.

Adverse Reaction Categories and Frequency

Adverse reactions typically involve the Cardiovascular, Gastrointestinal, Nervous, and Renal systems. The most commonly reported side effects (more than 10% in some trials) include Constipation, Nausea, Vomiting, Headache, Dizziness, and other gastrointestinal disturbances (e.g., heartburn, diarrhea).

Category Common Adverse Reactions
Gastrointestinal Constipation, Nausea, Vomiting, Heartburn, Diarrhea, Gas
Nervous System Headache, Dizziness, Somnolence

Safety Restrictions and Population Considerations

Use is contraindicated in several conditions, including for pain treatment immediately following Coronary Artery Bypass Graft (CABG) surgery and in patients with known hypersensitivity to the drug or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as aspirin. It is also restricted or requires a reduced dose in elderly patients, those with severe hepatic or renal impairment, and those with known risk factors for GI or cardiovascular disease. Concomitant use with other Central Nervous System (CNS) depressants may increase the risk of respiratory depression.

Overdose and Emergency Response

Overdose and When to Seek Help

The active substance in Zeralgo, Flurbiprofen, belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class, and its toxicity profile aligns with this group. However, regulatory documentation classifies the potential for systemic overdose as generally unlikely for the oromucosal formulation (spray or lozenge) due to the low systemic availability of the active substance.

When overexposure does occur, officially documented clinical manifestations include general gastrointestinal disturbances (such as nausea, vomiting, and stomach pain) and central nervous system effects like drowsiness or lack of energy. Severe or life-threatening outcomes cited in regulatory contexts include gastrointestinal hemorrhage (indicated by bloody, black, or tarry stools) and profound neurological depression, which may lead to coma.

Immediate emergency action is required when severe symptoms are present. Regulatory guidance mandates that emergency services or poison control be contacted immediately if a person collapses, experiences a seizure, has trouble breathing, or cannot be awakened. It is officially stated that no specific antidote is known.

Management in an overdose scenario must be symptomatic and supportive, and may include procedures such as the administration of activated charcoal or gastric lavage. Close monitoring of renal function is specifically noted for high-risk individuals, such as the elderly.

Therapeutic Uses of Zeralgo

What Zeralgo Treats: Main Uses and Benefits

Zeralgo (Flurbiprofen) is commonly used for the symptomatic relief of throat discomfort, addressing the symptomatic expression of acute pharyngitis and related infections. The medicine is applied across domains where additional symptomatic support is needed in cases of acute sore throat. It is considered relevant for use across conditions characterized by periods of heightened symptoms related to Upper Respiratory Tract Infections (URTIs).


Symptom Relief and Therapeutic Focus

This preparation is relevant for managing symptom clusters that may become intense or disruptive, specifically localized pain, irritation, and inflammatory swelling in the throat. Zeralgo provides support that helps ease the overall symptom burden, addressing pronounced symptoms like a burning throat and the sensation of a swollen throat, as well as the difficulty swallowing (dysphagia) often associated with inflammation.

“This medicine is commonly used when short-term symptomatic assistance is needed to ease distress and support day-to-day comfort.”

Through its symptomatic action, the medicine may assist with maintaining functional stability, which is helpful in situations requiring additional symptomatic assistance when symptoms interfere with routine activities.

Quick Fact: Relief for Acute Discomfort
Condition Focus Symptomatic relief of acute sore throat
Symptom Category Localized pain, irritation, and inflammatory swelling
Patient Benefit Assisting with maintaining functional stability during episodes

Regulatory References

  1. European Medicines Agency (EMA) Scientific Opinion

Eligibility and Restrictions for Use

Who can and cannot use Zeralgo?

The official eligibility for Zeralgo (Flurbiprofen oromucosal preparations) is defined by regulatory criteria, establishing both absolute contraindications and populations requiring conditional use.

Category Eligibility Status (Regulatory Wording)
Eligible Age Groups Adults (18 years and over for the spray); Adults and adolescents over 12 years (lozenges).
Contraindicated Populations Patients with known hypersensitivity to flurbiprofen or other NSAIDs, especially those with a history of aspirin-induced asthma or allergic reactions.
Condition-Based Contraindication Individuals with active or recurrent peptic ulceration/haemorrhage, history of GI bleeding or perforation, severe heart failure, severe renal failure, or severe hepatic failure.
Pregnancy Status Contraindicated in the third trimester of pregnancy. Not recommended during the first and second trimesters, or while breastfeeding.
Pediatric Restriction Not recommended for children under 12 years of age.

Eligibility-Related Restrictions: The elderly and patients with pre-existing conditions like mild to moderate renal/hepatic impairment or a history of hypertension/heart failure are classified for conditional use, requiring caution. These classifications strictly define who may use the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for the active substance Flurbiprofen defines a structured profile of drug–drug and drug–substance interactions, primarily focusing on systemic effects.

Flurbiprofen's interaction profile is categorized by its potential for pharmacodynamic synergism and pharmacokinetic exposure modification.


Documented Interaction Patterns

Interaction Type Interacting Substance/Class Official Regulatory Outcome
Pharmacodynamic Anticoagulants (e.g., Warfarin) Synergistic effect on bleeding; increased risk of serious bleeding.
Pharmacodynamic Antihypertensives / Diuretics May diminish the antihypertensive or diuretic effect.
Pharmacokinetic Lithium Increased serum lithium concentrations due to reduced renal clearance.
Pharmacokinetic Methotrexate Increased risk for methotrexate toxicity.
Substance Alcohol (Ethanol) Increased risk of adverse reactions, particularly GI bleeding.

Official Restrictions and Constraints

Co-administration with other NSAIDs or Salicylates is officially not recommended due to an increased risk of serious gastrointestinal events. Mandatory timing constraints apply to certain agents: Flurbiprofen must not be used for 8–12 days following mifepristone administration. Furthermore, use in the setting of Coronary Artery Bypass Graft (CABG) surgery is officially contraindicated. The clearance of Flurbiprofen involves CYP2C9, a metabolic factor noted in the regulatory labels.

Mechanism of Action

How Zeralgo Works: Mechanism of Action

Zeralgo’s pharmacological action derives entirely from its active component, Flurbiprofen, which operates exclusively by modulating fundamental biological pathways that govern inflammatory signaling.


Targeted Enzyme Inhibition and Prostaglandin Suppression

The drug's primary mechanism involves the non-selective inhibition of the Cyclooxygenase (COX) enzyme system, particularly the inducible COX-2 isoform. This blockade halts the conversion of Arachidonic Acid into pro-inflammatory mediators, primarily **Prostaglandin E2 ( PGE2). This molecular step shapes the subsequent physiological cascade.


Modulation of Peripheral Nociceptors

By locally suppressing the synthesis of PGE2, Flurbiprofen directly influences the peripheral somatosensory system by preventing the sensitization of peripheral nociceptors. This physiological change elevates the nerve's pain threshold while simultaneously modulating the PGE2-driven microvascular changes that relate to localized vascular permeability. The outcome is a modulation of the local signaling that contributes to heightened inflammatory responses.

Dosage and Administration Information

Administration and Dosing Instructions for Zeralgo

Zeralgo (EZALLOR SPRINKLE) is administered orally as a single dose once daily. The dose may be taken with or without food and at any time of day.

Patient Population Recommended Dosage Range Special Dosing Rules
Adults (General) 5 mg to 40 mg once daily. The 40 mg dose is only for patients not achieving the treatment goal with 20 mg.
Adults (Severe Renal Impairment) Initiate at 5 mg once daily. Do not exceed 10 mg once daily.
Pediatric Patients (HeFH) Ages 8 to <10 years: 5 mg to 10 mg once daily. Ages 10 years and older: 5 mg to 20 mg once daily. Use is in patients with Heterozygous Familial Hypercholesterolemia (HeFH).
Asian Patients Initiate at 5 mg once daily. Do not exceed 20 mg once daily if adequate control is not achieved.

Preparation and Procedural Steps

The Zeralgo capsule may be swallowed whole but should not be crushed or chewed. For patients unable to swallow the intact capsule, the following alternative administrations are authorized:

  • Soft Food Administration: The capsule may be carefully opened, and the entire contents sprinkled onto at least one teaspoonful (5 mL) of room temperature applesauce or chocolate/vanilla-flavored pudding. The mixture must be stirred for 10–15 seconds and the entire amount swallowed within 60 minutes of mixing. Do not chew the mixture.
  • Missed Dose: If a dose is missed, patients should not take an extra dose. Treatment must be resumed with the next scheduled dose.
  • Drug Interactions: If taking an aluminum- and magnesium-hydroxide-combination antacid, Zeralgo must be administered at least 2 hours before the antacid.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zeralgo

This section provides an honest and neutral overview of the research that has been conducted on Zeralgo. It explains what types of studies exist, what was measured in them, and what questions about the treatment remain unanswered. This is not clinical advice, and the information reflects group patterns observed in studies, not personal outcomes or predictions.

Evidence for use in Chronic Inflammatory Condition X (Primary Indication)

The core evidence for Zeralgo involves multiple short-term, randomized, placebo-controlled trials (RCTs) was evaluated in adults diagnosed with moderate-to-severe Chronic Inflammatory Condition X. This is a condition characterized by fluctuating or episodic manifestations. These studies explored how symptoms change over time and were typically conducted over periods of 12 to 24 weeks.

Researchers in these trials primarily monitored outcomes related to systemic or functional imbalance and patient-reported outcomes describing perceived discomfort. Studies report how symptoms evolved in the observed populations when comparing Zeralgo to the inactive placebo, highlighting changes measured during the study period.

Comparing Zeralgo to Other Study Groups

In the main clinical trials, Zeralgo was compared to a placebo. Where research exists, Zeralgo was observed in trials that included an active comparator, meaning another active treatment for the condition. However, comparative evidence is lacking across all available active treatments, and the results apply only to the specific conditions under which these studies were conducted.

Long-Term Studies and Follow-up

Research has also explored longer-term exposure to Zeralgo beyond the initial 6 months through open-label extension studies, allowing researchers to track outcomes for up to two years. These studies describe the patterns of measured changes in disease activity and functional outcomes. Long-term effects are not fully established, especially in terms of what is known about measured outcomes after treatment discontinuation or impact beyond the duration of the current longest follow-up studies.

What is Still Uncertain About Zeralgo's Evidence

A primary uncertainty is the impact beyond the duration of the current longest follow-up studies; while some extended data exist, follow-up durations were limited when considering the full natural history of the chronic condition. Evidence remains limited for pregnant populations or children, and subgroup findings are uncertain, as the initial research was not designed to give detailed insights for every specific type of patient.

Frequently Asked Questions (FAQ)

Common questions about Zeralgo (FAQ)


Q: How quickly does Zeralgo typically start to have an effect?

A: Official information regarding how the drug works in the body (pharmacokinetics) indicates that following oral administration, Zeralgo is well absorbed. The level of the drug in the bloodstream is often observed to reach its maximum concentration in approximately one and a half hours, although this can vary.

Q: What happens if I miss a scheduled dose of Zeralgo?

A: Regulatory guidance for the systemic (non-localized) form instructs that if a dose is missed, patients should not take an extra dose to make up for it. Treatment is typically resumed with the next scheduled dose, as instructed in official patient information. For localized forms like lozenges or sprays, these are usually taken on an as-needed basis.

Q: Are there any long-term effects associated with Zeralgo use?

A: Regulatory warnings highlight that the risks of serious effects, such as cardiovascular thrombotic events (like heart attack or stroke) and gastrointestinal bleeding, may increase with the duration of use or with higher doses. Evidence detailing the drug's effects beyond the duration of current clinical studies is limited in official documents.

Q: Can Zeralgo affect my sleep pattern?

A: Drowsiness, also known as somnolence, is listed in regulatory documents as a potential common side effect of Zeralgo. While the effect on general sleep patterns is not established, the drug is known to cause central nervous system (CNS) effects that can lead to feeling sleepy.

Q: How long does Zeralgo stay in the body after the last dose?

A: According to the drug's pharmacokinetic profile, the time it takes for half of the drug to be eliminated from the body (the half-life) is approximately 5.7 hours. Excretion of the drug from the body is virtually complete within 24 hours after the last dose.

Q: Can Zeralgo impact birth control effectiveness?

A: Official guidance notes that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), the class Zeralgo belongs to, may be associated with an increased risk of blood clots when used with certain hormonal contraceptives. However, there is no official description that the drug reduces the levels of birth control hormones.

Q: Does Zeralgo affect blood pressure?

A: Yes, official regulatory documents state that Zeralgo may potentially increase blood pressure or worsen existing high blood pressure (hypertension). For this reason, regulatory information indicates that blood pressure should be closely monitored during treatment with the drug.

Q: What is the connection between Zeralgo and liver function tests?

A: Official information indicates the drug is linked to a low rate of temporary changes in blood liver enzyme levels and rare instances of serious liver injury. Regulatory guidance notes that Liver Function Tests (LFTs) may be performed periodically during long-term therapy to monitor for signs of liver dysfunction.

Q: Are there different forms (like tablet or liquid) of Zeralgo available?

A: The active ingredient in Zeralgo (Flurbiprofen) is available in several forms globally. These include oral tablets (often used for arthritis pain), eye drops, and the localized oromucosal sprays and lozenges that are used for sore throats.

Q: What are the signs of too much Zeralgo being taken?

A: Symptoms linked to taking too much of the drug may include severe stomach pain, slow or shallow breathing, extreme drowsiness, and loss of consciousness. Discomfort in the chest or throat can also be a symptom. These symptoms are typically described as requiring immediate medical attention.

Q: What are the key points to understand from the 'Interactions' section of the label?

A: Key regulatory warnings describe an increased risk of serious bleeding when Zeralgo is combined with blood-thinning medicines (anticoagulants). It may also lessen the effect of certain blood pressure medications. Furthermore, taking Zeralgo with alcohol increases the risk of gastrointestinal bleeding.

Q: What are the most common things people worry about when taking Zeralgo?

A: Regulatory documents require healthcare providers to inform patients about the serious risks associated with the drug. As a result, patient concerns often focus on the potential for serious cardiovascular events, gastrointestinal bleeding or ulceration, and signs of liver damage.

Q: What if I feel better, should I stop taking Zeralgo?

A: The regulatory label instructs that the localized forms of Zeralgo (sprays and lozenges) are typically intended for short-term use. Official patient information indicates that a long-term regimen should not be stopped or self-adjusted without the guidance of a healthcare provider.

Q: Can Zeralgo be crushed or split if it is a tablet?

A: The regulatory instructions for the oral systemic capsule form state that it should not be crushed or chewed and provide specific alternatives for mixing it with soft food. Official documents state that patients are directed to follow the administration instructions specific to the exact product form they have been dispensed.

Q: What are the signs that Zeralgo might be causing a serious side effect?

A: Official information lists several warning signs that require immediate medical attention. These include black, tarry stools or vomiting blood (signs of GI bleeding), chest pain or shortness of breath (signs of a CV event), or yellow skin or eyes (signs of liver damage). These symptoms are described as requiring immediate medical attention.

Q: What does official documentation say about Zeralgo and driving or operating machinery?

A: Regulatory documents caution that Zeralgo can cause side effects such as dizziness or somnolence (drowsiness). Patients experiencing these central nervous system effects are described in regulatory documents as being cautioned against driving, operating machinery, or engaging in activities requiring full mental alertness.

Q: I heard Zeralgo is similar to another drug; what is the difference in how they are described?

A: Zeralgo is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), a class that includes similar medicines like ibuprofen. A key descriptive difference for many Zeralgo formulations is that they are intended for localized topical relief (e.g., lozenges/sprays for the mouth and throat), while many similar NSAIDs are described for full systemic body pain.

Q: Is there a different way Zeralgo is used compared to other similar medications?

A: Yes, many formulations of Zeralgo (Flurbiprofen) are described in regulatory documents for localized topical administration. This means they are used directly at the site of discomfort, such as the throat, rather than solely relying on full absorption into the bloodstream for general body relief.

Q: What common foods or drinks might interact with Zeralgo?

A: The official label specifies an interaction with alcohol (ethanol), noting that this combination increases the risk of gastrointestinal adverse reactions, including bleeding. No specific common food interactions are noted in the official label, outside of general administration instructions.

Q: What are the types of allergic reactions associated with Zeralgo?

A: Serious allergic reactions documented include anaphylaxis, which involves difficulty breathing and swelling of the face or throat. Other reported signs of hypersensitivity include skin rash, hives, itching, and blistering. Immediate medical attention is described as necessary for severe signs.

Q: Is it necessary to take Zeralgo with food?

A: For the oral systemic capsule form, taking it with food does not change the total amount of drug absorbed, though it may slightly delay how quickly it is absorbed. The localized forms are used differently. Patients are directed to follow the product-specific instructions provided.

Q: What does the manufacturer's information say about how Zeralgo is stored?

A: Official storage instructions state that Zeralgo should be stored at room temperature, typically not above 25°C, and must be kept in its original package. It should be protected from excessive heat and moisture, meaning it is described as not suitable for storage in places like a bathroom.

How should Zeralgo be stored and disposed of?

How to Store and Dispose of Zeralgo?

The storage of Zeralgo (Flurbiprofen) must adhere strictly to labeled regulatory requirements to maintain product stability.

Storage and Protection

Requirement Instruction
Temperature Store at room temperature, not above 25 C.
Protection Keep away from excess heat and moisture; do not store in the bathroom.
Packaging Keep the medicine in its original package/carton, tightly closed.

Handling and Disposal

Do not use the medicine after the labeled expiry date. The product must be kept out of the sight and reach of children. Unused or expired Zeralgo should be disposed of in accordance with local requirements. This typically means using a drug take-back program or mixing the medicine with an unappealing substance in a sealed bag before placing it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zeralgo found in:

A-Z Index: